SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Internet Computer (IC) is the world’s first blockchain that is capable of running at web speed at unrestrictive capacities. Built by the DFINITY Foundation, IC aims to recreate the web by supporting smart contract development at scale and changing the way people can interact using web services. Internet Computer aims to extend the public internet, so that it can be the world’s computing platform, in a decentralized manner. Internet Computer sets to revolutionalize the design of the crypto economy, with an aim to overhaul traditional software services.   The project was founded in October 2016 by Dominic WIllams and have raised a total of $121 million from investors such as Adreessen Horowitz, Polychain Capital, Multicoin Capital and such. On May 10, 2021, DFINITY launched the Internet Computer into the public domain, marking it a major milestone for ICP as it means the internet now functions as a decentralised global computer. This is marked by the release of all of the Internet Computer’s source code into the public domain, as well as ICP utility token that allows tens of thousands of community members to govern the Internet Computer network.  ICP is Internet Computer's native token. It plays three prominent roles:  1. Network Governance: Users that participate in the governance will be rewarded with ICPI 2. Production of Cycles for Compute: ICP can be converted into cycles where it is used as the transaction fee to access the network. Cycles are burned after used. 3. Rewarding Users: ICP is used as the rewards to incentivize users to participate in the network such as securing the network.

Internet Computer

Internet Computer (ICP) is trending as the community discusses its potential driven by developments like Caffeine AI, which allows for easy app creation. Bullish sentiment is building, with some community members drawing comparisons to previous rallies of other cryptocurrencies and anticipating a significant price increase. The discussion also highlights ICP's technology as a decentralized alternative to traditional cloud services.

COTI is a fast and light confidentiality layer on Ethereum. Powered by the breakthrough cryptographic protocol Garbled Circuits and secured by Ethereum, COTI introduces the most advanced and compliant solution for data protection on the public blockchain. Paving the way for the next wave of Web3 innovation and adoption, COTI unlocks a whole new world of use cases, including confidential transactions, Artificial Intelligence, DeFi, decentralized identification, and more.

COTI

COTI is trending as the community discusses its potential in the privacy sector and its partnerships, with some comparing it favorably to ZCash. Community members are actively speculating on future price targets and highlighting COTI's technology, emphasizing its potential for growth within the crypto space. The discussion also references AI and potential tokenized asset use cases.

The Filecoin network achieves staggering economies of scale by allowing anyone worldwide to participate as storage providers. It also makes storage resemble a commodity or utility by decoupling hard-drive space from additional services. On this robust global market the price of storage will be driven by supply and demand, not corporate pricing departments, and miners will compete on factors like reputation for reliability as well as price.

Filecoin

Filecoin is trending as the community discusses its potential in decentralized data storage and AI infrastructure, fueled by speculation of a mega squeeze. Bullish sentiment is high, with many highlighting its utility and anticipating a continued climb. However, some investors express frustration with its historical performance.

Amentum Holdings, Inc. provides mission-critical, technology-driven services in government and commercial markets. It operates through two operating segments: Critical Mission Solutions and Cyber & Intelligence. The Critical Mission Solutions segment provides test, training, and operations services for missile defense systems, IT and engineering services to defense clients and the space sector, technological solutions, including installations, decommissioning, and environmental remediation to energy clients, and other highly technical consulting solutions. The Cyber & Intelligence segment provides advanced cyber training and data analytics for government professionals, advanced communication systems and aerial mapping technologies to national security clients, and other technical services for United States defense and intelligence clients. The company was founded on November 26, 2019 and is headquartered in Chantilly, VA.

Amentum Holdings Inc.

Amentum Holdings ($AMTM) is gaining attention as investors discuss its potential to land a prime contract and its position as a major government service provider. Community members are comparing $AMTM to competitors with higher valuations and speculating about factors influencing its trading behavior. Some are also highlighting potential catalysts like earnings, contract awards, and long-term growth opportunities in areas like nuclear and defense.

Casey's General Stores, Inc. engages in the provision of management and operation of convenience stores and gasoline stations. It provides self-service gasoline, a wide selection of grocery items, and an array of freshly prepared food items. The firm offers food, beverages, tobacco products, health and beauty aids, automotive products, and other non-food items. The company was founded by Donald F. Lamberti in 1968 and is headquartered in Ankeny, IA.

Casey`s General Stores, Inc.

Casey's General Stores, Inc.

Casey's General Stores is trending as investors discuss its solid financial performance and expansion plans, particularly the acquisition of Fikes Wholesale. Community members are weighing in on its long-term growth potential, comparing it to other convenience store chains, and commenting on its diverse offerings like pizza and fuel. Positive analyst ratings and raised price targets are also contributing to the increased attention.

NEAR Protocol is the blockchain for AI. A high-performance, AI-native platform built to power the next generation of decentralized applications and intelligent agents. It provides the infrastructure AI needs to transact, operate, and interact across Web2 and Web3. NEAR combines three core elements: User-Owned AI, which ensures agents act in users’ best interests; Intents and Chain Abstraction, which eliminate blockchain complexity for seamless, goal-driven transactions across chains; and a sharded blockchain architecture that delivers the scalability, speed, and low-cost execution needed for real-world AI and Web3 use. This integrated stack makes NEAR the foundation for building secure, user-owned, AI-native applications at internet scale.

Near

NEAR is trending as community members discuss its potential within the AI sector and speculate about future price targets. Some investors are accumulating, viewing NEAR as undervalued, while others cite NEAR's role in cross-chain technology, decentralized finance, and data ownership. The discussion includes speculation around partnerships and technical analysis.

Avnet, Inc. engages in the provision of distribution and sale of electronic components. It operates through the Electronic Components and Farnell segments. The Electronic Components segment markets and sells semiconductors, interconnect, passive and electromechanical devices, and integrated components. The Farnell segment focuses on the distribution of electronic components and related products to the electronic system design community utilizing multi-channel sales and marketing resources. The company was founded by Charles Avnet in 1921 and is headquartered in Phoenix, AZ.

Avnet Inc.

Avnet is trending due to mixed reactions to earnings, with the company beating estimates but offering a dim outlook. Community members are weighing the implications of the guidance, and some are looking at Avnet's strategic shifts, such as its focus on embedded solutions and cloud services, for long-term potential. Overall, investors are assessing whether the near-term headwinds outweigh the company's strategic moves and dividend increases.

Oil States International, Inc. engages in the provision of manufactured products and services used in the drilling, completion, subsea, production, and infrastructure sectors of the oil and natural gas industry, as well as in the industrial and military sectors. It operates through the following segments: Offshore Manufactured Products, Completion and Production Services, Downhole Technologies, and Corporate. The Offshore Manufactured Products segment is involved in the design, manufacture, and market of capital equipment utilized on floating production systems, subsea pipeline infrastructure, and offshore drilling rigs and vessels, along with short-cycle, and other products. The Completion and Production Services segment focuses on the provision of equipment and services that are used to establish and maintain the flow of oil and natural gas from a well throughout its life cycle. The Downhole Technologies segment refers to the provision of oil and gas perforation systems and downhole tools in support of completion, intervention, wireline, and well abandonment operations. The Corporate segment represents the corporate expenses, such as those related to corporate governance, stock-based compensation, and other infrastructure support. The company was founded in July 1995 and is headquartered in Houston, TX.

Oil States International, Inc.

Oil States International is trending due to Susquehanna updating its rating to Neutral with a target between 5.5 and 6.5. The community is discussing the company's strong performance despite challenging conditions, with some speculating about a potential rise to $8 or even a buyout. Broader conversations include energy sector rebounds and the impact of rising oil production on equipment demand.

Kadena is launching one of the world’s first true scalable blockchains ready for applications.   Kadena’s public blockchain is a braided, high-throughput Proof of Work system that runs Chainweb, a protocol that delivers security and throughput. The Kadena network will unite public applications, private blockchains, and other interoperable chains in one place, driving traffic to the high-bandwidth computer at the heart of the Kadena public chain.  Kadena enterprise software is in use today by major companies in finance, healthcare, and insurance while allowing builders with a vision to skip straight from idea to product. With the launch of Kadena’s public chain, this system will support blockchain application development, from private to public and everywhere in between.    Kadena is solving the problems of Ethereum and is delivering features today that other blockchains have only begun to include on their roadmaps, including Formal Verification, interoperability, scalability, and more.  Kadena is live and ready for immediate deployment of production blockchain applications.  The Kadena token (KDA) is a digital currency that is used to pay for computation on the Kadena public chain. Similar to ETH on Ethereum, KDA on Kadena is the token in which miners are compensated for mining blocks on the network and is the transaction fee that users pay in order to have their transactions included in a block.  Applications processing volumes of transactions on the high-throughput, scalable Kadena network will execute their smart contract code using the native Kadena token. As more applications join or interoperate with the Kadena network, the number of smart contracts executed grows, as does the utility of the Kadena token.

Kadena

Kadena is trending amid community discussions around recent delistings from exchanges and the dissolving of its foundation, leading to price volatility. Some community members express concerns about the project's future, while others remain optimistic, citing ongoing development efforts and potential for a turnaround.  Bullish investors point to Kadena's technology and potential for future gains, drawing comparisons to other successful cryptocurrencies.

Cornerstone Strategic Value Fund is a management investment company that is an investment operation. They limit the fund's investment in securities issued by other investment companies.

Cornerstone Strategic Investment Fund Inc.

Cornerstone Strategic Investment Fund, Inc.

CLM is trending as investors discuss its recent price volatility and upcoming ex-dividend date, with some expressing concerns about a potential rights offering. The community is actively monitoring NAV and premiums, strategizing around DRIP and potential market reactions. Some investors are reporting difficulties trading the stock on certain platforms.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

NVO vs. GPCR: Which Obesity Stock is the Better Buy Right Now?

Novo Nordisk faces headwinds and leadership shifts, while Structure Therapeutics eyes pivotal obesity-drug data later this year.

Analysts delivered mixed verdicts on Eli Lilly after the drugmaker released late-stage trial results for its investigational oral weight-loss drug Orforglipron, sending shares sharply lower on Thursday.<a href="https://stocktwits.com/symbol/LLY">Eli Lilly shares</a> closed down 14.1% at $640.86 on Thursday,&nbsp;their worst session since Aug. 9, 2000,&nbsp;but climbed in after-hours trading. The stock is now at lows last seen in early 2024.Leerink downgraded Eli Lilly to ‘Market Perform’ from ‘Outperform’ and cut its price target to $715 from $944, calling the results “disappointing” and lowering its long-term projections.&nbsp;The firm stated that its investment thesis had&nbsp;shifted and no longer&nbsp;anticipated upward pressure on consensus estimates, warning of rising GLP-1 competition by the end of the decade, even as rival Novo Nordisk faces pricing pressure.BofA, by contrast, called Eli Lilly’s second quarter (Q2) earnings and FY25 guidance raise “refreshing” compared with Novo’s “troubled” quarter, saying the drop in Lilly’s stock was “way overdone” and created a buying opportunity.&nbsp;The bank kept its ‘Buy’ rating and $1,000 price target, saying Eli Lilly remains “in pole position in obesity.”The Phase 3 ATTAIN-1 trial in 3,127 adults with obesity or overweight showed patients on the highest 36 mg dose l<a href="https://stocktwits.com/news-articles/markets/equity/nifty-sensex-recover-to-end-in-green-august-7/chrmRMkRddF">ost an average of 12.4% of body weight</a>, or 27.3 pounds, at 72 weeks, with nearly 60% losing at least 10%.&nbsp;Lilly stated that safety was consistent with injectable GLP-1 drugs, such as Mounjaro. The company plans to seek regulatory approval by the end of the year.H.C. Wainwright’s Joseph Pantginis said Viking Therapeutics’ VK2735 “remains a standout” after comparing discontinuation rates favorably with Eli Lilly’s data. The firm reiterated its ‘Buy’ rating on Viking with a $102 target and raised its target for Structure Therapeutics to $75 from $60, citing the potential of its oral GLP-1 candidate aleniglipron.Eli Lilly also lifted its 2025 revenue guidance midpoint by $1.5 billion to $60 billion–$62 billion and now expects adjusted EPS of $21.75–$23.The company’s Q2 revenue jumped 38% to $15.56 billion, with $5.2 billion from Mounjaro and $3.38 billion from Zepbound. Adjusted EPS was $6.31, topping forecasts.On Stocktwits, retail sentiment for Eli Lilly, which was among the top three trending tickers, was ‘extremely bullish’ amid a 1,228% surge in 24-message volume.One user on Stocktwits said they believed Eli Lilly shares would rebound eventually, but not immediately, noting that with Friday approaching and the rest of the world yet to react, it might be better to wait before adding more calls or shares.<stembedurl>https://stocktwits.com/SIbilisWhisper/message/624244609</stembedurl>Another user commented that they had bought as much stock as they could, calling it “way oversold” despite what they viewed as an extremely bullish earnings report, adding that stock market makers “are a mystery.”<stembedurl>https://stocktwits.com/Mypointofbay/message/624237111</stembedurl>Eli Lilly’s stock has declined&nbsp;about 17% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, an Eli Lilly and Company logo seen displayed on a smartphone. (Photo Illustration by Igor Golovniov/SOPA Images/LightRocket via Getty Images)

Eli Lilly Stock Marks Worst Day In 25 Years As Weight-Loss Pill Data Disappoints: Analysts Divided But Retail Bets On Rebound

A late-stage study tested three doses of Eli Lilly’s oral GLP-1 drug, Orforglipron, in more than 3,100 adults, with the highest dose resulting in an average weight loss of 27.3 pounds over 72 weeks.

Equity

Pfizer Inc.'s (PFE) decision to halt the development of its oral GLP-1 candidate due to a potential liver toxicity issue could pose tailwinds for smaller biotech rivals, according to Wall Street analysts.According to The Fly, JPMorgan thinks Pfizer's scrapping of its&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/pfizer-ends-development-of-weight-loss-pill-danuglipron/chfCPelRba2">danuglipron</a> program opens the door for Structure Therapeutics’ (GPCR)GSBR-1290 (aleniglipron) to become the second small molecule oral GLP-1 to reach the market.It also makes Viking Therapeutics' (VKTX) an "even more attractive partnership candidate," the analyst said.Meanwhile, BTIG also flagged Viking as a key beneficiary, reiterating its 'Buy' rating and $125 price target, implying a 400% upside from the last close.&nbsp;The research firm pointed to Viking's "competitive" oral candidate VK2735, currently in Phase 2 trials, with data expected in the second half of 2025.&nbsp;A Phase 3 study for the injectable form is also set to begin in the second quarter.Media reports suggest Pfizer could now look to external assets. BTIG said it remains focused on Viking's "compelling pipeline and data" regardless of Pfizer's next steps.Retail sentiment for Viking Therapeutics turned 'bullish' late Monday from 'bearish' a day ago, accompanied by an 8,220% surge in message volume.<figure class="image"><img style="aspect-ratio:1318/316;" src="https://news.stocktwits-cdn.com/VKTX_sentiment_and_message_volume_on_April_14_png_16bef741c1.webp" alt="VKTX sentiment and message volume on April 14.png" width="1318" height="316"><figcaption>VKTX sentiment and message volume on April 14. | source: Stocktwits</figcaption></figure>One user thought Viking's stock "should be up 30-40%" as it has the "best in class oral GLP-1 now."<stembedurl>https://stocktwits.com/rxptgh/message/611544179</stembedurl>Another watcher speculated that Pfizer could likely buy Viking Therapeutics following the news.<stembedurl>https://stocktwits.com/KnysnaNow/message/611596706</stembedurl>Structure Therapeutics, meanwhile, saw its sentiment meter jump into 'extremely bullish' levels from 'bearish' a day ago.<figure class="image"><img style="aspect-ratio:1318/316;" src="https://news.stocktwits-cdn.com/GPCR_sentiment_and_message_volume_on_April_14_png_6c34839d3e.webp" alt="GPCR sentiment and message volume on April 14.png" width="1318" height="316"><figcaption>GPCR sentiment and message volume on April 14. | source: Stocktwits</figcaption></figure>A bullish user said the company's aleniglipron "is going to be best in class" among GLP-1 oral pills, and CEO Ray Stevens "knows it's an easy winner and big money."<stembedurl>https://stocktwits.com/DAR2487/message/611630051</stembedurl>Structure's stock is down over 30% year to date, while Viking's has lost nearly 40%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

One user thought Viking's stock "should be up 30-40%" as it has the "best in class oral GLP-1 now."

Wall Street Sees Pfizer's Weight-Loss Pill Exit As A Win For 2 Smaller Biotech Firms: Retail Turns Bullish

Investors are now considering the possibility of Pfizer acquiring either of these companies as it looks for external candidates.

 Wall Street Sees Pfizer's Weight-Loss Pill Exit As A Win For Viking, Structure Therapeutics

Structure CEO on the competitive landscape for oral GLP-1 drugs

Raymond Stevens, Structure Therapeutics CEO, joins 'Fast Money' to talk its oral GLP-1 offerings...

Promising Outlook for Structure Therapeutics with Strong Pipeline and Financial Stability

JMP Securities analyst Jonathan Wolleben reiterated a Buy rating on Structure Therapeutics, Inc. Sponsored ADR (GPCR Research Report) today and s...

Buy Rating Backed by Strategic Partnership Opportunities and Strong Patent Portfolio for Structure Therapeutics

Leerink Partners analyst David Risinger has reiterated their bullish stance on GPCR stock, giving a Buy rating on July 22. David Risinger has given...

Obesity-Drugs Focused Stocks Tumble On Wednesday - What's Going On With Eli Lilly, Novo Nordisk, Viking Therapeutics, Structure Therapeutics?

Eli Lilly, Novo Nordisk, Viking Therapeutics, and Structure Therapeutics shares are down following Roche's promising CT-996 trial results for type 2 diabetes and obesity. Get insights into the latest...

Obesity-Drugs Focused Stocks Tumble On Wednesday - What's Going On With Eli Lilly, Novo Nordisk, Viking Therapeutics, Structure Therapeutics...

Peering Into Structure Therapeutics's Recent Short Interest

Structure Therapeutics CEO on GLP drugs

Structure Therapeutics CEO on GLP drugs...

Structure Therapeutics, Inc. is a clinical stage global biopharmaceutical company, which engages in developing novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its pipeline includes Aleniglipron GSBR-1290, ACCG-2671, GIPR, GCGR, ANPA-0073, and LTSE-2578. The company was founded by Raymond C. Stevens in 2016 and is headquartered in South San Francisco, CA.

Structure Therapeutics Inc - ADR

$ASTS

$RKLB

$BBAI

$NBIS

Which earnings release are you most excited for the week of Nov. 10? 
 
Drop a comment for others.

GPCR
Structure Therapeutics Inc - ADR

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest GPCR News

GPCRStructure Therapeutics Inc - ADR